MedTrace Logo

Iloprost in Acute Respiratory Distress Syndrome

NCT03111212 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-12-30

No results posted yet for this study

Summary

The patients will be randomized into one of two groups. Both groups will receive standard care as is state of the art. The intervention group will receive Iloprost nebulized as inhalative therapy.

Conditions

  • Respiratory Distress Syndrome, Adult

Interventions

DRUG

Iloprost

Iloprost nebulized

DRUG

control

sodium chloride 0,9% nebulized

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Peter Rosenberger, MD · University Hospital Tuebingen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-25
Primary Completion
2021-05-14
Completion
2021-08-14

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03111212 on ClinicalTrials.gov